Selvas Healthcare, Near FDA Approval in US, Invests in Innovative Companies... "AI Telemedicine Full-Scale Launch"

Selvas AI's subsidiary, Selvas Healthcare, is acquiring shares in UltraSight, an AI-based cardiac diagnostic imaging innovation company.

On the 12th, Selvas Healthcare announced that it will acquire 424,000 shares of UltraSight. The strategy is to actively advance the 'AI telemedicine business' by acquiring shares in UltraSight, which is awaiting approval from the U.S. FDA.

UltraSight's AI cardiac ultrasound solution obtained the CE mark in Europe and the UKCA mark in the United Kingdom last year. The U.S. FDA approval process is currently underway.

In February, global company GE Healthcare acquired AI imaging company Caption Health, increasing worldwide interest in the AI ultrasound market.

UltraSight's 'AI cardiac ultrasound' combines portable ultrasound devices with AI imaging intelligence technology to provide cardiac ultrasound diagnostic guidance. Emergency ultrasound examinations can be performed not only by medical professionals but also by medical staff with low ultrasound proficiency, enabling cardiac ultrasound measurements at all patient care locations including clinics, regional hospitals, screening centers, and remote areas.

Yoo Byung-tak, CEO of Selvas Healthcare, stated, "Following our existing digital healthcare business, we are expanding into the AI telemedicine market," and added, "We plan to fully launch the AI telemedicine business through the integration of Selvas AI's artificial intelligence technology and UltraSight's technology and services, which are awaiting U.S. FDA approval."

Selvas Healthcare is expanding its new business into the AI telemedicine market and AI medical diagnostics market, following its existing digital healthcare business. By combining Selvas Healthcare's hardware (HW) manufacturing capabilities with its parent company Selvas AI's software (SW) technology and IT services, it is promoting the AI telemedicine business. Additionally, by integrating UltraSight's AI ultrasound guidance technology, the company plans to accelerate the advancement of the AI telemedicine business.